These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36311639)

  • 1. Lead exposure as a causative factor for metabolic associated fatty liver disease (MAFLD) and a lead exposure related nomogram for MAFLD prevalence.
    Yang C; Li Y; Ding R; Xing H; Wang R; Zhang M
    Front Public Health; 2022; 10():1000403. PubMed ID: 36311639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD.
    Chen J; Mao X; Deng M; Luo G
    Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):394-401. PubMed ID: 36695773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of MAFLD and NAFLD using different screening indexes: A cross-sectional study in U.S. adults.
    Peng H; Pan L; Ran S; Wang M; Huang S; Zhao M; Cao Z; Yao Z; Xu L; Yang Q; Lv W
    Front Endocrinol (Lausanne); 2023; 14():1083032. PubMed ID: 36742412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of metal mixtures with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2003-2018.
    Xie Z; Aimuzi R; Si M; Qu Y; Jiang Y
    Front Public Health; 2023; 11():1133194. PubMed ID: 36950101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of five hepatic steatosis algorithms in metabolic-associated fatty liver disease: A population based study.
    Liu Y; Liu S; Huang J; Zhu Y; Lin S
    J Gastroenterol Hepatol; 2022 May; 37(5):938-945. PubMed ID: 35174539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study.
    Xie ZQ; Li HX; Wang BK; Yang ZM; Zhang ZY; Tan WL; Li WX; Wang QB; Yang L; Zhuang HK; Tang CW; Shang CZ; Chen YJ
    Eur J Intern Med; 2023 Apr; 110():62-70. PubMed ID: 36754655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of MAFLD and NAFLD diagnostic criteria in real world.
    Lin S; Huang J; Wang M; Kumar R; Liu Y; Liu S; Wu Y; Wang X; Zhu Y
    Liver Int; 2020 Sep; 40(9):2082-2089. PubMed ID: 32478487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic-associated fatty liver disease and the risk of cardiovascular disease.
    Zhang P; Dong X; Zhang W; Wang S; Chen C; Tang J; You Y; Hu S; Zhang S; Wang C; Wen W; Zhou M; Tan T; Qi G; Li L; Wang M
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102063. PubMed ID: 36494073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis.
    Muthiah M; Ng CH; Chan KE; Fu CE; Lim WH; Tan DJH; Nah B; Kong G; Xiao J; Yong JN; Tan B; Syn N; Wang JW; Sayed N; Tan E; Chew NW; Dan YY; Siddiqui MS; Sanyal AJ; Noureddin M
    Ann Hepatol; 2023; 28(1):100762. PubMed ID: 36182031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Establishment and Analysis of Risk Prediction Model for Metabolic Dysfunction-Associated Fatty Liver Disease in Physical Examination Population].
    Xia B; He H; Qin K; Li SQ; An ZM
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):591-595. PubMed ID: 37248589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of a nomogram for predicting metabolic-associated fatty liver disease in the Chinese physical examination population.
    Zhou B; Gong N; Huang X; Zhu J; Qin C; He Q
    Lipids Health Dis; 2023 Jun; 22(1):85. PubMed ID: 37386566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between self-reported snoring and metabolic-associated fatty liver disease: A cross-sectional analysis of the NHANES 2017-2018.
    Wang Y; Shen R; Ge J
    Sleep Med; 2023 Jan; 101():414-420. PubMed ID: 36516525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAFLD and risk of CKD.
    Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
    Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population.
    Cai J; Lin C; Lai S; Liu Y; Liang M; Qin Y; Liang X; Tan A; Gao Y; Lu Z; Wu C; Huang S; Yang X; Zhang H; Kuang J; Mo Z
    Lipids Health Dis; 2021 Oct; 20(1):145. PubMed ID: 34706716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a new nomogram to screen for MAFLD.
    Zou H; Zhao F; Lv X; Ma X; Xie Y
    Lipids Health Dis; 2022 Dec; 21(1):133. PubMed ID: 36482400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study.
    Chen YL; Li H; Li S; Xu Z; Tian S; Wu J; Liang XY; Li X; Liu ZL; Xiao J; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
    BMC Gastroenterol; 2021 May; 21(1):212. PubMed ID: 33971822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999-2016.
    Zhang HJ; Wang YY; Chen C; Lu YL; Wang NJ
    Chin Med J (Engl); 2021 Jun; 134(13):1593-1601. PubMed ID: 34091530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
    Liu D; Shen Y; Zhang R; Xun J; Wang J; Liu L; Steinhart C; Chen J; Lu H
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1670-1678. PubMed ID: 33140878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact on Prevalence of the Application of NAFLD/MAFLD Criteria in Overweight and Normal Weight Patients.
    Ordoñez-Vázquez AL; Juárez-Hernández E; Zuarth-Vázquez JM; Ramos-Ostos MH; Uribe M; Castro-Narro G; López-Méndez I
    Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between endocrine disrupting chemicals and MAFLD: Evidence from NHANES survey.
    Lei R; Xue B; Tian X; Liu C; Li Y; Zheng J; Luo B
    Ecotoxicol Environ Saf; 2023 May; 256():114836. PubMed ID: 37001192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.